Jianzhi Education Technology Announces Agreement with SeaArt AI, One of the World's Top 20 Generative AI Platforms

Jianzhi Education Technology Announces Agreement with SeaArt AI, One of the World's Top 20 Generative AI Platforms

BEIJING, June 1, 2026 /PRNewswire/ -- Jianzhi Education Technology Group Company Limited (the "Company" or "Jianzhi") (NASDAQ: JZ), a leading EdTech company in China, today announced that it has entered into an agreement (the "Agreement") with...

SEG Solar Announces Third U.S. Factory, Becoming Largest Domestic Solar Manufacturer at 10.6 GW Capacity

SEG Solar Announces Third U.S. Factory, Becoming Largest Domestic Solar Manufacturer at 10.6 GW Capacity

HOUSTON, June 1, 2026 /PRNewswire/ -- SEG Solar ("SEG"), a leading U.S. solar module manufacturer, today announced plans to develop its third U.S. manufacturing facility in Greater Houston, Texas. The new 4.6-gigawatt (GW) facility is expected to...

Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026

Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026

Clinically Meaningful Overall Antitumor Activity, with ORR of 42.9% and DCR of 95.9% across all evaluated dose levels in heavily pretreated patients. Enhanced Clinical Activity at the Recommended Phase 2 Dose (RP2D), with ORR of 50% in patients who...

Eason Technology Announces the Formation of New Subsidiary, Four Ele Industrial Intelligent Tech to Target Power Energy, Energy Networks and New Energy Storage Facilities Scenarios

Eason Technology Announces the Formation of New Subsidiary, Four Ele Industrial Intelligent Tech to Target Power Energy, Energy Networks and New Energy Storage Facilities Scenarios

HONG KONG, June 1, 2026 /PRNewswire/ -- Eason Technology Limited ("Eason" or the "Company") (NYSE American: DXF), today announced the launch of a new wholly owned subsidiary, Four Ele Industrial Intelligent Tech. The Company plans for Four Ele...

OCI Global Announces Sale of 50% of OCI Nitrogen to AGROFERT

OCI Global Announces Sale of 50% of OCI Nitrogen to AGROFERT

AMSTERDAM, June 1, 2026 /PRNewswire/ -- OCI Global (Euronext: OCI) ("OCI" or the "Company") today announces that it has reached an agreement to divest 50% of its equity interest in Nitrogen Intermediate Holding B.V. (which owns 100% of "OCI...

Unitree Announces H2 Plus, an NVIDIA Isaac GR00T Reference Humanoid Robot for Academic Research

Unitree Announces H2 Plus, an NVIDIA Isaac GR00T Reference Humanoid Robot for Academic Research

News Summary: Unitree Robotics introduces H2 Plus, an NVIDIA Isaac GR00T Reference Humanoid Robot combining a Unitree H2 humanoid robot, Sharpa five-fingered hands for dexterous manipulation, NVIDIA Jetson Thor for advanced reasoning and control,...

XPENG Announces Vehicle Delivery Results for May 2026

XPENG Announces Vehicle Delivery Results for May 2026

GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global AI mobility technology company, today announced its vehicle delivery results for May 2026. XPENG delivered a total of...

Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting

Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting

HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today announced updated...

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

HANGZHOU, China, SHANGHAI and BOSTON, June 1, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that its...

Yozma Announces Landmark Football Partnership for 1st Anniversary

Yozma Announces Landmark Football Partnership for 1st Anniversary

Partnership with the Belgian Red Devils marks a major step in Yozma's global brand evolution. DENVER, May 30, 2026 /PRNewswire/ -- To mark its first anniversary, Yozma has announced a landmark partnership as the North America regional dirt-bike...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 71
  • menu
    menu